Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA Pharmacokinetics in Moderate Hepatic Impairment
NCT03606538Phase 1Not yet recruiting
- Sponsor
- Lykos Therapeutics
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of midomafetamine in post-traumatic stress disorder (PTSD) (2 arms), sponsored by Lykos Therapeutics. Primary endpoints: Area under curve from dosing time to last measurement (AUC(0-t)) for MDMA and Area under curve from dosing time to last measurement (AUC(0-t)) for MDA. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03606538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03606538.